Progress in the Diagnosis and Classification of Pituitary Adenomas

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2015 Jul 1

PMID 26124750

Citations 22

Authors

Luis V Syro

Fabio Rotondo

Alex Ramirez

Antonio Di Ieva

Murat Aydin Sav

Lina M Restrepo

Carlos A Serna

Kalman Kovacs

Affiliations

Soon will be listed here.

Abstract

Pituitary adenomas are common neoplasms. Their classification is based upon size, invasion of adjacent structures, sporadic or familial cases, biochemical activity, clinical manifestations, morphological characteristics, response to treatment and recurrence. Although they are considered benign tumors, some of them are difficult to treat due to their tendency to recur despite standardized treatment. Functional tumors present other challenges for normalizing their biochemical activity. Novel approaches for early diagnosis, as well as different perspectives on classification, may help to identify subgroups of patients with similar characteristics, creating opportunities to match each patient with the best personalized treatment option. In this paper, we present the progress in the diagnosis and classification of different subgroups of patients with pituitary tumors that may be managed with specific considerations according to their tumor subtype.

Citing Articles

Immunohistochemical Patterns of Pituitary Adenomas in Southeastern Nigeria, a 10-year Histopathologic Review.

Nwokoro O, Ukekwe F, Nzegwu M, Okafor O, Uche E Libyan J Med. 2023; 18(1):2245587.

PMID: 37575085 PMC: 10431727. DOI: 10.1080/19932820.2023.2245587.

Prognostic Factors for Invasiveness and Recurrence of Pituitary Adenomas: A Series of 94 Patients.

Stefanidis P, Kyriakopoulos G, Seretis A, Korfias S, Theocharis S, Angelousi A Diagnostics (Basel). 2022; 12(10).

PMID: 36292101 PMC: 9600140. DOI: 10.3390/diagnostics12102413.

Major Genetic Motifs in Pituitary Adenomas: A Practical Literature Update.

Agrawal N, Gersey Z, Abou-Al-Shaar H, Gardner P, Mantica M, Agnihotri S World Neurosurg. 2022; 169:43-50.

PMID: 36115566 PMC: 11195535. DOI: 10.1016/j.wneu.2022.09.036.

Extracting clinical named entity for pituitary adenomas from Chinese electronic medical records.

Fang A, Hu J, Zhao W, Feng M, Fu J, Feng S BMC Med Inform Decis Mak. 2022; 22(1):72.

PMID: 35321705 PMC: 8941801. DOI: 10.1186/s12911-022-01810-z.

Alterations in CD8 Tregs, CD56 Natural Killer Cells and IL-10 Are Associated With Invasiveness of Nonfunctioning Pituitary Adenomas (NFPAs).

Huang X, Xu J, Wu Y, Sheng L, Li Y, Zha B Pathol Oncol Res. 2021; 27:598887.

PMID: 34257554 PMC: 8262195. DOI: 10.3389/pore.2021.598887.

References

Asa S, Ezzat S . The pathogenesis of pituitary tumors. Annu Rev Pathol. 2009; 4:97-126. DOI: 10.1146/annurev.pathol.4.110807.092259. View

Bender A, Beavo J . Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58(3):488-520. DOI: 10.1124/pr.58.3.5. View

Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis S . Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab. 2015; 100(5):E710-9. PMC: 4422891. DOI: 10.1210/jc.2014-4297. View

Toledo S, Lourenco Jr D, Toledo R . A differential diagnosis of inherited endocrine tumors and their tumor counterparts. Clinics (Sao Paulo). 2013; 68(7):1039-56. PMC: 3715026. DOI: 10.6061/clinics/2013(07)24. View

Boikos S, Stratakis C . Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Hum Mol Genet. 2007; 16 Spec No 1:R80-7. DOI: 10.1093/hmg/ddm019. View

Heaney A . Clinical review: Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011; 96(12):3649-60. PMC: 3277423. DOI: 10.1210/jc.2011-2031. View

Sav A, Rotondo F, Syro L, Ieva A, Cusimano M, Kovacs K . Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin North Am. 2015; 44(1):99-104. DOI: 10.1016/j.ecl.2014.10.008. View

Reid T, Post K, Bruce J, Kanibir M, Reyes-Vidal C, Freda P . Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf). 2009; 72(2):203-8. PMC: 2866138. DOI: 10.1111/j.1365-2265.2009.03626.x. View

Trivellin G, Daly A, Faucz F, Yuan B, Rostomyan L, Larco D . Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014; 371(25):2363-74. PMC: 4291174. DOI: 10.1056/NEJMoa1408028. View

10.

Buchfelder M . Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2008; 12(3):256-60. DOI: 10.1007/s11102-008-0153-z. View

11.

Beckers A, Aaltonen L, Daly A, Karhu A . Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013; 34(2):239-77. PMC: 3610678. DOI: 10.1210/er.2012-1013. View

12.

Colao A, Grasso L, Pivonello R, Lombardi G . Therapy of aggressive pituitary tumors. Expert Opin Pharmacother. 2011; 12(10):1561-70. DOI: 10.1517/14656566.2011.568478. View

13.

Thakker R . Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010; 24(3):355-70. DOI: 10.1016/j.beem.2010.07.003. View

14.

Leontiou C, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S . The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008; 93(6):2390-401. DOI: 10.1210/jc.2007-2611. View

15.

Lopes M . Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus. 2010; 29(4):E2. DOI: 10.3171/2010.7.FOCUS10169. View

16.

Ieva A, Davidson J, Syro L, Rotondo F, Montoya J, Horvath E . Crooke's cell tumors of the pituitary. Neurosurgery. 2015; 76(5):616-22. DOI: 10.1227/NEU.0000000000000657. View

17.

Kiseljak-Vassiliades K, Carlson N, Borges M, Kleinschmidt-DeMasters B, Lillehei K, Kerr J . Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine. 2014; 49(1):231-41. PMC: 4331291. DOI: 10.1007/s12020-014-0383-y. View

18.

Chesnokova V, Melmed S . Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol. 2010; 326(1-2):55-9. PMC: 2906651. DOI: 10.1016/j.mce.2010.02.012. View

19.

Mete O, Asa S . Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol. 2013; 30(3):158-64. DOI: 10.1053/j.semdp.2013.06.002. View

20.

Melmed S . Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011; 7(5):257-66. DOI: 10.1038/nrendo.2011.40. View